Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?
NTLA Stock Plunges on Trial Halt Intellia’s stock implosion began early Monday after the biotech stunned investors with news of a trial pause. Before the market opened on Oct. 27, the Cambridge, MA-based